Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

Summary

The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms.

Timeline

Start

2022-03-31

Primary completion

2025-07-30

Completion

2025-07-31

Drugs

Indications